Abstract 3073
Background
Management of Ca treatment-related symptoms is an important safety issue. The value of nursing in symptom management is critical and becoming increasingly so as the treatment becomes more remarkably complex.
Methods
Qualitative research Descriptive case study Describe the problems of a 28year old dx with Hodgkin’s Disease.
Results
Chemotherapy Day Hospital (CDH) was the 1st contact with the oncology reality Focus: familiarization with a hostil atmosphere develop links between patient-nurses change of routines impact on ADL management of CT’s effects therapeutic regimen increase one’s resilience and hope while in treatment reduce long-term complications of the Ca tips to promote comfort: minimize suffering assisting patient navigation in the care continuum Relapse after 6 months New CT treatment (inpatient setting) Anxiety attacks due to the adaptation/awareness of his new condition Focus: management of bad news and CT’s side effects requested collaboration to the nurse of the CDH in the adaptation of strategies of adhesion to the new CT/hospitalization hospital routines adapted to his habits self care promotion psychological support articulation between services communication among nurses - promote the continuity of care New relapse Began immunotherapy: hospitalized after pulmonar toxicity In this scope he performed a bronchoscopy No curative therapy indication Due to tiredness/dyspnea a personalized respiratory rehabilitation plan was developed by a nurse: breathing optimization energy conservation techniques teaching positions of rest/relaxation In the end-of-life were adopted non-pharmacological strategies: relief of dyspnea (guidelines of the nurse of the bronchoscopy unit) positioning massage distraction techniques his mother was allowed to spend the night with him D/C was possible to fulfill one of his desires After a month he was admitted (neurological changes) and passed away.
Conclusions
During the treatment period of the disease the patient went through 3 distinctive services where it was necessary to have an individualized/specialized approach as well as an articulation/communication among the nurses in order to guarantee an effectively management of symptoms and the quality/safety of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract